Donor-Specific Antibodies Against Donor Human Leukocyte Antigen are Associated with Graft Inflammation but Not with Fibrosis Long-Term After Liver Transplantation: An Analysis of Protocol Biopsies

References

• Londoño M-C, Souza LN, Lozano -J-J, et al. Molecular profiling of subclinical inflammatory lesions in long-term surviving adult liver transplant recipients. J Hepatol. 2018;69(3):626–634. doi:10.1016/j.jhep.2018.04.012
   PubMed Web of Science ®Google Scholar
• Yoshitomi M, Koshiba T, Haga H, et al. Requirement of protocol biopsy before and after complete cessation of immunosuppression after liver transplantation. Transplantation. 2009;87(4):606–614. doi:10.1097/TP.0b013e318195a7cb
   PubMed Web of Science ®Google Scholar
• Vergani D, Mieli-Vergani G. Autoimmunity after liver transplantation: autoimmunity after liver transplantation. Hepatology. 2002;36(2):271–276. doi:10.1053/jhep.2002.35339
   PubMed Web of Science ®Google Scholar
• Sebagh M. All liver recipients benefit from the protocol 10-year liver biopsies. Hepatology. 2003;37(6):1293–1301. doi:10.1053/jhep.2003.50231
   PubMed Web of Science ®Google Scholar
• Kerkar N, Hadzic N, Davies ET, et al. De-novo autoimmune hepatitis after liver transplantation. Lancet. 1998;351(9100):409–413. doi:10.1016/S0140-6736(97)06478-7
   PubMed Web of Science ®Google Scholar
• Heneghan M. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. Hepatology. 2001;34(3):464–470. doi:10.1053/jhep.2001.26756
   PubMed Web of Science ®Google Scholar
• O’Leary JG, Kaneku H, Jennings L, Susskind BM, Terasaki PI, Klintmalm GB. Donor-specific alloantibodies are associated with fibrosis progression after liver transplantation in hepatitis C virus-infected patients: donor-specific antibodies and fibrosis progression. Liver Transpl. 2014;20(6):655–663. doi:10.1002/lt.23854
   PubMed Web of Science ®Google Scholar
• Tait BD, Süsal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplant J. 2013;95(1):19–47. doi:10.1097/TP.0b013e31827a19cc
   PubMed Web of Science ®Google Scholar
• Colvin RB. Dimensions of antibody-mediated rejection: editorial. Am J Transplant. 2010;10(7):1509–1510. doi:10.1111/j.1600-6143.2010.03172.x
   PubMed Web of Science ®Google Scholar
• Witt CA, Gaut JP, Yusen RD, et al. Acute antibody-mediated rejection after lung transplantation. J Heart Lung Transplant. 2013;32(10):1034–1040. doi:10.1016/j.healun.2013.07.004
   PubMed Web of Science ®Google Scholar
• Demetris AJ, Bellamy COC, Gandhi CR, Prost S, Nakanuma Y, Stolz DB. Functional immune anatomy of the liver-as an allograft. Am J Transplant. 2016;16(6):1653–1680. doi:10.1111/ajt.13749
   PubMed Web of Science ®Google Scholar
• Halloran PF, Venner JM, Madill-Thomsen KS, et al. Review: the transcripts associated with organ allograft rejection. Am J Transplant. 2018;18(4):785–795. doi:10.1111/ajt.14600
   PubMed Web of Science ®Google Scholar
• Demetris AJ, Bellamy C, Hübscher SG, et al. 2016 comprehensive update of the Banff working group on liver allograft pathology: introduction of antibody-mediated rejection. Am J Transplant. 2016;16(10):2816–2835. doi:10.1111/ajt.13909
   PubMed Web of Science ®Google Scholar
• Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, et al. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts: posttransplant Hla DSA S, C4 D, and Late Graft Fibrosis. Liver Transpl. 2012;18(11):1333–1342. doi:10.1002/lt.23534
   PubMed Web of Science ®Google Scholar
• O’Leary JG, Kaneku H, Demetris AJ, et al. Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss: antibody-mediated liver transplant rejection. Liver Transpl. 2014;20(2):218–227. doi:10.1002/lt.23788
   PubMed Web of Science ®Google Scholar
• Kaneku H, O’Leary JG, Taniguchi M, Susskind BM, Terasaki PI, Klintmalm GB. Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation: i G G subclass DSA S in chronic liver rejection. Liver Transpl. 2012;18(8):984–992. doi:10.1002/lt.23451
   PubMed Web of Science ®Google Scholar
• O’Leary JG, Cai J, Freeman R, et al. Proposed diagnostic criteria for chronic antibody-mediated rejection in liver allografts: chronic AMR in liver transplant. Am J Transplant. 2016;16(2):603–614. doi:10.1111/ajt.13476
   PubMed Web of Science ®Google Scholar
• Cousin VL, Rougemont A-L, Rubbia-Brandt L, et al. Peripheral donor specific antibodies are associated with histology and cellular subtypes in protocol liver biopsies of pediatric recipients. Transplantation. 2019. doi:10.1097/TP.0000000000003099
   Google Scholar
• Yamada H, Kondou H, Kimura T, et al. Humoral immunity is involved in the development of pericentral fibrosis after pediatric live donor liver transplantation: pericentral fibrosis and humoral immunity. Pediatr Transplant. 2012;16(8):858–865. doi:10.1111/j.1399-3046.2012.01781.x
   PubMed Web of Science ®Google Scholar
• Teegen EM, Dürr M, Maurer MM, et al. Evaluation of histological dynamics, kidney function and diabetes in liver transplant patients after antiviral treatment with direct-acting antivirals: therapy of HCV-recurrence. Transpl Infect Dis. 2019;21(1):e13020. doi:10.1111/tid.13020
   PubMed Web of Science ®Google Scholar
• Del Bello A, Danjoux M, Congy-Jolivet N, et al. Histological long-term outcomes from acute antibody-mediated rejection following ABO-compatible liver transplantation: outcome of antibody mediated rejection. J Gastroenterol Hepatol. 2017;32(4):887–893. doi:10.1111/jgh.13613
   PubMed Web of Science ®Google Scholar
• Legaz I, Boix F, López M, et al. Influence of preformed antibodies in liver transplantation. JCM. 2020;9(3):708. doi:10.3390/jcm9030708
   Google Scholar
• Höfer A, Jonigk D, Hartleben B, et al. Non-invasive screening for subclinical liver graft injury in adults via donor-specific anti-HLA antibodies. Sci Rep. 2020;10(1):14242. doi:10.1038/s41598-020-70938-7
   PubMed Web of Science ®Google Scholar
• Koch M, Marget M, Sterneck M, Fischer L, Thude H, Nashan B. Limited impact of pre-existing donor specific HLA-antibodies (DSA) on long term allograft survival after first adult liver transplantation. Hum Immunol. 2018;79(7):545–549. doi:10.1016/j.humimm.2018.04.009
   PubMed Web of Science ®Google Scholar
• Muro M. The endless history or search for the true role of alloantibodies in liver transplantation. Clin Res Hepatol Gastroenterol. 2020;101544. doi:10.1016/j.clinre.2020.09.005
   PubMed Web of Science ®Google Scholar
• Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994;19(6):1513–1520. doi:10.1002/hep.1840190629
   PubMed Web of Science ®Google Scholar
• Ekong UD, Melin-Aldana H, Seshadri R, et al. Graft histology characteristics in long-term survivors of pediatric liver transplantation. Liver Transpl. 2008;14(11):1582–1587. doi:10.1002/lt.21549
   PubMed Web of Science ®Google Scholar
• Varma S, Ambroise J, Komuta M, et al. Progressive fibrosis is driven by genetic predisposition, allo-immunity, and inflammation in pediatric liver transplant recipients. EBioMedicine. 2016;9:346–355. doi:10.1016/j.ebiom.2016.05.040
   PubMed Web of Science ®Google Scholar
• Straub RH, Schradin C. Chronic inflammatory systemic diseases: an evolutionary trade-off between acutely beneficial but chronically harmful programs. Evol Med Public Health. 2016;2016(1):37–51. doi:10.1093/emph/eow001
   PubMedGoogle Scholar
• Furman D, Campisi J, Verdin E, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019;25(12):1822–1832. doi:10.1038/s41591-019-0675-0
   PubMed Web of Science ®Google Scholar
• Schnitzbauer AA, Filmann N, Adam R, et al. mTOR inhibition is most beneficial after liver transplantation for hepatocellular carcinoma in patients with active tumors. Ann Surg. 2020;272(5):855–862. doi:10.1097/SLA.0000000000004280
   PubMed Web of Science ®Google Scholar
• Willuweit K, Heinold A, Rashidi-Alavijeh J, et al. Immunosuppression with mTOR inhibitors prevents the development of donor-specific antibodies after liver transplant. Clin Transplant. 2017;31(6):e12974. doi:10.1111/ctr.12974
   Web of Science ®Google Scholar
• Narumi S, Watarai Y, Goto N, et al. Everolimus-based immunosuppression possibly suppresses mean fluorescence intensity values of de novo donor-specific antibodies after primary kidney transplantation. Transplant Proc. 2019;51(5):1378–1381. doi:10.1016/j.transproceed.2019.03.019
   PubMed Web of Science ®Google Scholar
• Perbos E, Juinier E, Guidicelli G, et al. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors. Clin Transplant. 2014;28(9):1054–1060. doi:10.1111/ctr.12418
   PubMed Web of Science ®Google Scholar
• Bartlett AS, Ramadas R, Furness S, Gane E, McCall JL. The natural history of acute histologic rejection without biochemical graft dysfunction in orthotopic liver transplantation: a systematic review. Liver Transpl. 2002;8(12):1147–1153. doi:10.1053/jlts.2002.36240
   PubMed Web of Science ®Google Scholar
• Taubert R, Pischke S, Schlue J, et al. Enrichment of regulatory T cells in acutely rejected human liver allografts: treg enrichment in rejected liver allografts. Am J Transplant. 2012;12(12):3425–3436. doi:10.1111/j.1600-6143.2012.04264.x
   PubMed Web of Science ®Google Scholar
• Loupy A, Vernerey D, Tinel C, et al. Subclinical rejection phenotypes at 1 year post-transplant and outcome of kidney allografts. JASN. 2015;26(7):1721–1731. doi:10.1681/ASN.2014040399
   Web of Science ®Google Scholar
• Kim PTW, Demetris AJ, O’Leary JG. Prevention and treatment of liver allograft antibody-mediated rejection and the role of the ‘two-hit hypothesis’. Curr Opin Organ Transplant. 2016;21(2):209–218. doi:10.1097/MOT.0000000000000275
   PubMed Web of Science ®Google Scholar
• Levitsky J, Kaneku H, Jie C, Walsh RC, Abecassis M, Tambur AR. Donor-specific HLA antibodies in living versus deceased donor liver transplant recipients. Am J Transplant. 2016;16(8):2437–2444. doi:10.1111/ajt.13757
   PubMed Web of Science ®Google Scholar
• O’Leary JG, Kaneku H, Banuelos N, Jennings LW, Klintmalm GB, Terasaki PI. Impact of IgG3 subclass and C1q-fixing donor-specific HLA alloantibodies on rejection and survival in liver transplantation: igG3 and C1q-fixing DSA in liver transplantation. Am J Transplant. 2015;15(4):1003–1013. doi:10.1111/ajt.13153
   PubMed Web of Science ®Google Scholar
• Ohe H, Uchida Y, Yoshizawa A, et al. Association of anti-human leukocyte antigen and anti-angiotensin II type 1 receptor antibodies with liver allograft fibrosis after immunosuppression withdrawal. Transplantation. 2014;98(10):1105–1111. doi:10.1097/TP.0000000000000185
   PubMed Web of Science ®Google Scholar
• Kaneku H, O’Leary JG, Banuelos N, et al. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients: de novo DSA in liver transplantation. Am J Transplant. 2013. doi:10.1002/ajt.12212
   PubMedGoogle Scholar
• O’Leary JG, Klintmalm GB. Impact of donor-specific antibodies on results of liver transplantation. Curr Opin Organ Transplant. 2013;18(3):279–284. doi:10.1097/MOT.0b013e3283614a10
   PubMed Web of Science ®Google Scholar
• Crispe IN. Immune tolerance in liver disease. Hepatology. 2014;60(6):2109–2117. doi:10.1002/hep.27254
   PubMed Web of Science ®Google Scholar
• Höfer A, Jonigk D, Hartleben B, et al. DSA are associated with more graft injury, more fibrosis, and upregulation of rejection-associated transcripts in subclinical rejection. Transplantation. 2020;104(3):551–561. doi:10.1097/TP.0000000000003034
   PubMed Web of Science ®Google Scholar
• Musat AI, Agni RM, Wai PY, et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation: HLA alloantibodies in liver allograft rejection. Am J Transplant. 2011;11(3):500–510. doi:10.1111/j.1600-6143.2010.03414.x
   PubMed Web of Science ®Google Scholar
• O’Leary JG, Kaneku H, Susskind BM, et al. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant: DSA found in post-OLT chronic rejection. Am J Transplant. 2011;11(9):1868–1876. doi:10.1111/j.1600-6143.2011.03593.x
   PubMed Web of Science ®Google Scholar
• Takaya S, Jain A, Yagihashi A, et al. Increased bile duct complications and/or chronic rejection in crossmatch positive human liver allografts. Transplant Proc. 1999;31(5):2028–2031. doi:10.1016/s0041-1345(99)00256-0
   PubMed Web of Science ®Google Scholar
• Iacob S, Cicinnati VR, Dechêne A, et al. Genetic, immunological and clinical risk factors for biliary strictures following liver transplantation. Liver Int. 2012;32(8):1253–1261. doi:10.1111/j.1478-3231.2012.02810.x
   PubMed Web of Science ®Google Scholar
• den Dulk AC, Shi X, CorneliaJ V, et al. Donor-specific anti-HLA antibodies are not associated with nonanastomotic biliary strictures but both are independent risk factors for graft loss after liver transplantation. Clin Transplant. 2018;32(2):e13163. doi:10.1111/ctr.13163
   Web of Science ®Google Scholar
• Muro M, R Moya-Quiles M, Mrowiec A. Humoral response in liver allograft transplantation: a review of the role of anti-Human Leukocyte Antigen (HLA) antibodies. CPPS. 2016;17(8):776–784. doi:10.2174/1389203717666160226145101
   Google Scholar